Skip to main content
SpringerLink
Log in

Tumeurs intestinales, quelle stratégie proposer?

Intestinal tumors: can a management strategy be proposed?

  • Published:
Acta Endoscopica

Résumé

Les tumeurs primitives de l’intestin grêle représentent seulement 50 % de toutes les tumeurs du tractus gastro-intestinal. Les manifestations cliniques de ces tumeurs ne sont pas spécifiques et leurs symptômes apparaissent tardivement. La rareté, la non spécificité des symptômes et leur inaccessibilité rend ces tumeurs de l’intestin grêle susceptibles de passer inaperçues, avec un diagnostic très souvent erroné et tardif, et d’être responsables d’un taux de mortalité élevé.

Le développement de la capsule endoscopique pour l’étude de l’intestin grêle et l’utilisation de l’imatinib dans les tumeurs stromales gastro-intestinales (TSGI) ont représenté d’importantes innovations dans le diagnostic et le traitement de ces patients. Cette étude a pour objet de discuter le rôle de ces deux nouveautés dans le traitement des tumeurs de l’intestin grêle et de proposer un algorithme pour leur diagnostic et traitement.

Summary

Primary small-bowel tumors are representing only 5 % of all primary tumors of the gastrointestinal tract. Clinical manifestations of these tumors are nonspecific and the neoplasmarelated symptoms occur lately. The rarity, non specific symptoms and inaccessibility make small bowel tumors liable to be overlooked, with frequent delayed or erroneous diagnosis, and are responsible for high mortality rates.

The development of capsule endoscopy for small bowel examination, as well as the use of imatinib in gastrointestinal stromal tumors (GIST), supposed outstanding innovations in diagnosis and therapy of these patients. The role of these two innovations in the management of small bowel tumors is discussed in this review and a diagnostic and therapeutic algorithm is proposed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Références

  1. Jemal A, Murray T, Samuels A, et al. Cancer Statistics, 2003. CA Cancer J Clin 2003; 53: 5–26.

    PubMed  Google Scholar 

  2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54 (1): 8–29.

    Article  PubMed  Google Scholar 

  3. DiSario JA, Burt RW, Vargas H, et al. Small bowel cancer: epidemiological and clinical characteristics from a populationbased registry. Am J Gastroenterol 1994; 89: 699–701.

    PubMed  CAS  Google Scholar 

  4. Neugut AI, Arber N. Epidemiology, molecular epidemiology, and molecular biology of small bowel and appendiceal adenocarcinomas. In: Abbruzzese J, ed. Principles and Practice of Gastrointestinal Oncology. Baltimore, Md: Lippincott Williams & Wilkins; 2001.

    Google Scholar 

  5. Jones DV Jr, Skibber J and Levin B. Adenocarcinoma and other small intestinal neoplasms, including benign tumors. In: Feldman M, Scharschmidt BF and Sleisenger MH. Gastrointestinal and liver disease: Pathophysiology, Diagnosis and Management. Philadelphia, WB Saunders Company; 1998.

    Google Scholar 

  6. Lance P. Tumors and other neoplastic diseases of the small intestine. In: Yamada T, Alpers DH, Laine L, Owyang C and Powell DW eds. Text book of Gastroenterology. Philadelphia, Lippincott Williams & Wilkins; 1999.

    Google Scholar 

  7. Frost DB, Mercado PD, Tyrell JS, et al. Small bowel cancer: a 30-year review. Ann Surg Oncol 1994; 1: 290–5.

    Article  PubMed  CAS  Google Scholar 

  8. Cunningham JD, Aleali R, Aleali M, et al. Malignant small bowel neoplasms: histopathologic determinants of recurrence and survival. Ann Surg 1997; 225: 300–6.

    Article  PubMed  CAS  Google Scholar 

  9. Ohja A, Zacherl J, Scheuba C et al. Primary small bowel malignancies: single-center results of three decades. J Clin Gastroenterol 2000; 30: 289–93.

    Article  Google Scholar 

  10. Bauer RL, Palmer ML, Bauer AM, et al. Adenocarcinoma of the small bowel intestine: 21-year review of diagnosis, treatment and prognosis. Annals of Surgical Oncology 1994; 1: 183–8.

    Article  PubMed  CAS  Google Scholar 

  11. Talamonti MS, Goetz LH, Rao S, et al. Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg 2002; 137: 564–71.

    Article  PubMed  Google Scholar 

  12. Yang Y-S, Huang Q-Y, Wang W-F, et al. Primary jejunoileal neoplasmas: a review of 60 cases. World J Gastroenterol 2003; 9: 862–4.

    PubMed  Google Scholar 

  13. North JH, Pack MS. Malignant tumors of the small intestine: a review of 144 cases. Am Surg 2000; 66: 46–51.

    PubMed  CAS  Google Scholar 

  14. García Marcilla JA, Sánchez Bueno F., Aguilar J, et al. Primary small bowel malignant tumors. Eur J Surg Oncol 1994; 20: 630–4.

    Google Scholar 

  15. Blanchard DK, Budde JM, Hatch GF 3rd. Tumors of the small intestine. World J Surg 2000; 24: 421–9.

    Article  PubMed  CAS  Google Scholar 

  16. Nolan DJ and Traill ZC. The current role of the barium examination of the small bowel. Clin Radiol 1997; 52: 809–20.

    Article  PubMed  CAS  Google Scholar 

  17. Bloomfeld RS, Smith TP, Schneider AM, Rockey DC. Provocative angiography in patients with gastrointestinal hemorrhage of obscure origin. Am J Gastroenterol 2000; 95: 2807–12.

    Article  PubMed  CAS  Google Scholar 

  18. Maccioni F, Rossi P, Gourtsoyiannis N, et al. Broglia L. US and CT findings of small bowel neoplasms. Eur Radiol 1997; 7: 1398–1409.

    Article  PubMed  CAS  Google Scholar 

  19. Landi B, Tkoub M, Gaudric M et al. Diagnostic yield of pushenteroscopy in relation to indication. Gut 1998; 42: 421–5.

    Article  PubMed  CAS  Google Scholar 

  20. Lewis B, Kornbluth A, Waye J. Small bowel tumors: the yield of enteroscopy. Gut 1991; 32: 763–7.

    Article  PubMed  CAS  Google Scholar 

  21. Douard R, Wind P, Panis Y, et al. Intraoperative enteroscopy for diagnosis and management of unexplained gastrointestinal bleeding. Am J Surg 2000;180:181–4.

    Article  PubMed  CAS  Google Scholar 

  22. Iddan G, Meron G, Glukhovsky A and Swain P. Wireless capsule endoscopy. Nature 2000; 405: 417.

    Article  PubMed  CAS  Google Scholar 

  23. Gong F, Swain P and Mills T. Wireless endoscopy. Gastrointest Endosc 2000; 51: 725–29.

    Article  PubMed  CAS  Google Scholar 

  24. Ell C, Remke S, May A, Helou L, Henrich R, Mayer G. The first prospective controlled trial comparing wireless capsule endoscopy with push enteroscopy in chronic gastrointestinal bleeding. Endoscopy 2002; 34: 685–9.

    Article  PubMed  CAS  Google Scholar 

  25. Lewis BS and Swain P. Capsule endoscopy in the evaluation of patients with suspected small intestinal bleeding: results of a pilot study. Gastrointest Endosc 2002; 56: 349–53.

    Article  PubMed  Google Scholar 

  26. Pennazio M, Santucci R, Rondonotti E, et al. Clinical outcome of patients with obscure gastrointestinal bleeding after capsule endoscopy: report of 100 consecutive cases. Gastroenterology 2004; 126: 643–53.

    Article  PubMed  Google Scholar 

  27. Herrerías JM, Caunedo A, Rodríguez-Téllez M, Pellicer FJ, Herrerías JM Jr. Capsule endoscopy in patients with suspected Crohn’s disease in negative endoscopy. Endoscopy 2003; 35: 564–9.

    Article  PubMed  Google Scholar 

  28. Fireman Z, Majan E, Broide E, et al. Diagnosing small bowel Crohn’s disease with wireless capsule endoscopy. Gut 2003; 52: 390–2.

    Article  PubMed  CAS  Google Scholar 

  29. Romero J, Gómez BJ, Caunedo A, et al. NSAIDs erosive enteropathy assessed by capsule endoscopy: a prospective controlled trial. Proceedings of the 3rd Conference on Capsule Endoscopy. Miami, 2004, 91.

  30. Graham DY, Qureshi WA, Willingham F et al. A controlled study of NSAID-induced small bowel injury using video capsule endoscopy. Gastroenterology 2003; 124: A19.

    Article  Google Scholar 

  31. Pennazio M, Arrigoni A, Sprujevnik T, Bertone A, Cavallero M, Spandre M, et al. Autoimmune polyglandular syndrome type II associated with gastrointestinal stromal tumor: diagnosis by capsule endoscopy. Endoscopy 2004; 36: 248–9.

    Article  PubMed  CAS  Google Scholar 

  32. Alcázar J, Romero J, Rodríguez-Téllez M, Caunedo A, Pellicer F and Herrerías JM. A 65-years-old woman with intense ferropenic anemia. Proceedings of 1st Iberian meeting on capsule endoscopy. Seville, 2003, 118.

  33. De Franchis R, Rondotti E, Abbiati C, et al. Small Bowel malignancy. Gastrointest Endosc Clin N Am 2004;14: 139–48.

    Article  PubMed  Google Scholar 

  34. Cobrin GM, Pittman RH and Lewis BS. Diagnosing small bowel tumors with capsule endoscopy. Proceedings of the 3rd Conference on Capsule Endoscopy. Miami, 2004, 41.

  35. Keuchel M, Thaler C, Caselitz J, and Hagenmuller F. Diagnosis of small bowel tumors with video capsule endoscopyreport of 16 cases. Proceedings of the 3rd Conference on Capsule Endoscopy. Miami, 2004, 43.

  36. Mascarenhas-Saraiva M, Da Silva LM. Small bowel tumors diagnosed by wireless capsule endoscopy: report of five cases. Endoscopy 2003; 35: 865–8.

    Article  PubMed  Google Scholar 

  37. Gay G, Laurent V, Fassler I, Delvaux M. Interest of the endoscopic videocapsule to detect intestinal tumors. Proceedings of the 3rd Conference on Capsule Endoscopy. Miami, 2004, 135.

  38. Menchén L, González-Asanza C, Díaz-Redondo A, De la Cruz G, Beceiro I, Alberdi J, et al. Small bowel neoplasms in patients with obscure gastrointestinal bleeding; diagnosis with capsule endoscopy. Endoscopy 2003; 35 [Suppl II]: A183.

    Google Scholar 

  39. Toth E, Fork FT, Syk I, Ljungberg O, Stewenius J, Lindström M, et al. Diagnosis of small bowel tumors by capsule endoscopy in patients with obscure gastrointestinal bleeding. Proceedings of the 3rd Conference on Capsule Endoscopy. Miami, 2004, 195.

  40. Romero-Vázquez J, Caunedo A, Alcázar J, et al. Tumores de intestino delgado en una serie de 400 capsuloendoscopias. Proceedings of the “ XXXV Reunión de la Sociedad Andaluza de Patología Digestiva”. Seville, 2004.

  41. Madisch A, Schimming W, Kinzel F, Schneider R, Aust D, Ockert DM, et al. Locally advanced small-bowel adenocarcinoma missed primarily by capsule endoscopy but diagnosed by push enteroscopy. Endoscopy 2003; 35: 861–5.

    Article  PubMed  CAS  Google Scholar 

  42. De Franchis R, Devani M, Randotti E, et al. Study of neuroendocrine neoplasms of the small Borrel with capsule endoscopy: report of two cases. Proceedings of the 3rd Conference on Capsule Endoscopy. Miami, 2004, 97.

  43. Caunedo A, Jimenez-Sáenz M, Romero R, Pellicer FJ, Herrerías JM. The role of capsule endoscopy in the assessment of gastrointestinal lymphomas. Proceedings of the 1st Conference on Capsule Endoscopy. Rome, 2002, 75.

  44. Jimenez-Sáenz M, Caunedo A, Rodríguez-Téllez M, Romero R, Herrerías JM et al. Capsule endoscopy in the surveillance of patients with primary small bowel lymphoma (case report). Proceedings of the 1st Conference on Capsule Endoscopy. Rome, 2002, 137.

  45. Blanke CD, Eisenberg BL, Heinrich MC. Gastrointestinal stromal tumors. Curr Treat Options Oncol 2001; 2: 485–91.

    Article  PubMed  CAS  Google Scholar 

  46. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995; 103: 41–7.

    PubMed  CAS  Google Scholar 

  47. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT). Gastrointestinal tumors of the jejunum and ileum. Mod Pathol 1997; 10: 200–9.

    Google Scholar 

  48. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577–80.

    Article  PubMed  CAS  Google Scholar 

  49. Ernst SI, Hubbs AE, Przygodzki RM, et al. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998; 78: 1633–6.

    PubMed  CAS  Google Scholar 

  50. Seidal T, Edvardsson H. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumors. Histopathology 1999; 34: 416–24.

    Article  PubMed  CAS  Google Scholar 

  51. Moskaluk CA, Tian Q, Marshall CR, et al. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene 1999; 18: 1897–1902.

    Article  PubMed  CAS  Google Scholar 

  52. Lasota J, Jasinski M, Sarlomo-Rikala M, et al. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154: 53–60.

    PubMed  CAS  Google Scholar 

  53. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59: 4297–4300.

    PubMed  CAS  Google Scholar 

  54. Heinrich MC, Rubin BP, Longley BJ, et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002; 33: 484–95.

    Article  PubMed  CAS  Google Scholar 

  55. Fletcher JA, Fletcher CD, Rubin BP, et al. KIT gene mutations in gastrointestinal stromal tumors: more complex than previously recognized? Am J Pathol 2002; 161: 737–8.

    PubMed  CAS  Google Scholar 

  56. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708–10.

    Article  PubMed  CAS  Google Scholar 

  57. Andersson J, Sjogren H, Meis-Kindblom JM, et al. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002; 160: 15–22.

    PubMed  CAS  Google Scholar 

  58. Gunawan B, Bergmann F, Hoer J, et al. Biological and clinical significance of cytogenetic abnormalities in low-risk and highrisk gastrointestinal stromal tumors. Hum Pathol 2002; 33: 316–21.

    Article  PubMed  Google Scholar 

  59. Demetri GD, Titton RL, Ryan DP, et al. Case 32–2004: A 68-year-old man with a large retroperitoneal mass. N Engl J Med 2004; 351: 1779–87.

    Article  PubMed  CAS  Google Scholar 

  60. Miettinen M, Lasota J. Gastrointestinal stromal tumors — definition, clinical, histological, immunohistochemical and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1–12.

    Article  PubMed  CAS  Google Scholar 

  61. Pidhorecky I, Cheney RT, Kaybill WG, et al. Gastrointestinal Stromal Tumors: Current Diagnosis, Biologic Behavior, and Management. Annals of Surgical Oncology, 2001; 7: 705–12.

    Article  Google Scholar 

  62. Blanke CD, Eisenberg BL, Heinrich MC. Gastrointestinal stromal tumors. Curr Treat Options Oncol 2001; 2: 485–91.

    Article  PubMed  CAS  Google Scholar 

  63. Suster S. Gastrointestinal stromal tumors. Semin Diagn Pathol 1996 Nov; 13 [4]: 297–313.

    PubMed  CAS  Google Scholar 

  64. Casper ES. Gastrointestinal stromal tumors. Curr Treat Options Oncol 2000; 1: 267–73.

    Article  PubMed  CAS  Google Scholar 

  65. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg 2001; 231: 51–8.

    Article  Google Scholar 

  66. Miettinen M, El-Rifai W, Sobin LH, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002; 33: 478–83.

    Article  PubMed  CAS  Google Scholar 

  67. Langer C, Gunawan B, Schuler P, et al. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 2003; 90: 332–9.

    Article  PubMed  CAS  Google Scholar 

  68. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: consensus approach. Hum Pathol 2002; 3: 459–65.

    Article  Google Scholar 

  69. Connolly EM, Gaffney E and Reynolds JV. Gastrointestinal stromal tumours. Br J Surg 2003; 90: 1178–86.

    Article  PubMed  CAS  Google Scholar 

  70. Buchdunger, E, Cioffi, CL, Law, N et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139–45.

    PubMed  CAS  Google Scholar 

  71. Savage DG, Antman KH. Imatinib mesylate — a new oral targeted therapy. N Engl J Med 2002; 346: 683–93.

    Article  PubMed  CAS  Google Scholar 

  72. Heinrich MC, Griffith DJ, Druker B et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000, 96: 925–32.

    PubMed  CAS  Google Scholar 

  73. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708–10.

    Article  PubMed  CAS  Google Scholar 

  74. Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 2003; 63: 513–27.

    Article  PubMed  CAS  Google Scholar 

  75. Kantarjian H, Sawyers C, Hochhaus A, et al. Hématologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–52.

    Article  PubMed  CAS  Google Scholar 

  76. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hématologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–37.

    Article  PubMed  CAS  Google Scholar 

  77. Sawyers CL, Hochhaus A, Feldman et al. Imatinib induces hematologie and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood 2002; 99: 3530–9.

    Article  PubMed  CAS  Google Scholar 

  78. Tuveson, D. A., Willis, N. A., Jacks, T., et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001; 20: 5054–8.

    Article  PubMed  CAS  Google Scholar 

  79. Mace J, Sybil Biermann J., Sondak V, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002; 95: 2373–9.

    Article  PubMed  CAS  Google Scholar 

  80. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052–6.

    Article  PubMed  CAS  Google Scholar 

  81. van Oosterom A, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421–3.

    Article  PubMed  Google Scholar 

  82. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472–80.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastro enterology Unit, «Virgen Macarena» University Hospital, Seville, Spain

    A. Caunedo & J. M. Herrerías

Authors
  1. A. Caunedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. Herrerías
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Caunedo, A., Herrerías, J.M. Tumeurs intestinales, quelle stratégie proposer?. Acta Endosc 35, 157–169 (2005). https://doi.org/10.1007/BF03009100

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03009100

Mots-clés

Key-words

Search

Navigation